CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
CVRx is focused on the development and commercialization of the Barostim System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit .MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast.
明尼阿波利斯，2024年11月20日（环球新闻社） - CVRx，Inc.（纳斯达克：CVRX）（"CVRx"），一家商业化阶段的医疗器械公司，今日宣布管理团队将于2024年12月4日星期三参加派杰投资第36届医疗健康大会。公司计划于当天下午3:30通过网络直播进行演示。
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com.
会议演示的现场音频网络直播将在公司网站的投资者关系页面ir.cvrx.com上线。
About CVRx, Inc.
CVRx, Inc. 简介。CVRx 是一家商业化医疗器械公司，专注于为心血管疾病患者开发、制造和销售创新的神经调节解决方案。Barostim 是首个 FDA 批准使用神经调节技术改善心力衰竭症状的医疗技术。Barostim 为可植入设备，向颈动脉壁的压力感受器提供电脉冲。该疗法旨在恢复自主神经系统的平衡，从而减轻心衰症状。Barostim 获得 FDA 创新设备认证，已获得 FDA 批准在美国人群中使用以治疗心衰病患者，也已获得欧洲经济区治疗心衰病和难治性高血压的 CE 认证。要了解有关 Barostim 的更多信息，请访问网站。
CVRx is focused on the development and commercialization of the Barostim System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit .
CVRx致力于开发和商业化Barostim系统，这是FDA首次批准使用神经调节改善心力衰竭症状的医疗技术。Barostim是一种植入式器械，它向颈动脉壁中的压力感受器传递电脉冲。压力感受器激活人体的压力感受器反射，进而触发自主神经对心脏的反应。该疗法旨在恢复自主神经系统的平衡，从而减轻心力衰竭的症状。Barostim获得FDA突破性设备认定，并获得美国心力衰竭患者使用的FDA批准。它还获得了欧洲经济区心力衰竭和难治性高血压的CE标志。欲了解Barostim的更多信息，请访问网站。
Investor Contact:
投资者联系人：
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Mark Klausner或Mike Vallie
ICR 医疗保健
443-213-0501
ir@cvrx.com
Media Contact:
媒体联系：
Laura O'Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
Laura O'Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
